Learn how to pick growth stocks using a data-driven framework. We break down the key metrics separating real compounders from expensive traps.
How to Pick Growth Stocks: A Data-Driven Framework
Most investors know they want growth stocks. Few have a repeatable process for finding them. The result is a portfolio full of high-multiple names bought on narrative, held through deterioration, and sold at exactly the wrong time. A data-driven framework fixes that.
This post walks through the core dimensions that separate genuine growth compounders from expensive stories. The examples come from stocks in the ACCE universe, using live data as of May 18, 2026.
Step 1: Separate Revenue Growth from Earnings Growth
Revenue growth gets the headlines. Earnings growth builds the case.
A company growing revenue at 30% while burning cash is a speculation. A company growing revenue at 15% while doubling earnings is a compounder. The distinction matters enormously when rates are elevated and multiple compression is a real risk.
Take Axon Enterprise (AXON) as a live example. Revenue grew 33.7% year-over-year, which is genuinely impressive for a company at its scale. But earnings grew 89.8% over the same period, meaning the business is not just growing, it is becoming more profitable as it scales. That earnings leverage is the signal worth chasing.
Contrast that with Beam Therapeutics (BEAM), which posted 324.9% revenue growth. That number looks extraordinary until you notice earnings are not calculable because the company is still pre-profit. Revenue growth without a path to earnings is a different kind of bet entirely.
The framework rule: require both revenue acceleration and a credible trajectory toward earnings growth. One without the other demands a much higher burden of proof.
Step 2: Interrogate the Valuation Gap
Growth stocks trade at premiums. The question is whether the premium is justified by the growth rate, and whether the forward multiple reflects a realistic deceleration.
The trailing P/E on a fast-growing company is almost always misleading. What matters is the forward P/E relative to the growth rate, sometimes called the PEG ratio, and whether the market is pricing in a realistic or optimistic scenario.
Axon again illustrates this well. The trailing P/E sits at 161.7, which looks alarming in isolation. The forward P/E drops to 37.8, reflecting the market's expectation that earnings will continue to scale rapidly. The analyst consensus target of $662.04 against a current price of $399.47 implies the market has not fully priced in that earnings trajectory. That gap between trailing and forward multiples is exactly where growth stock opportunities live.
Boston Scientific (BSX) shows a cleaner version of the same dynamic. Trailing P/E of 23.2, forward P/E of 14.7, and earnings growth of 100.0% year-over-year. The multiple compression from trailing to forward is steep, and the earnings growth rate justifies it. That kind of setup, where the forward multiple is reasonable relative to the growth rate, is the sweet spot for growth stock selection.
Step 3: Score the Business Quality, Not Just the Growth Rate
Growth rates mean nothing if the underlying business cannot sustain them. Quality filters prevent buying into cyclical spikes or one-time revenue events that get mistaken for durable growth.
The dimensions that matter most:
- Gross margin trajectory: Is the business getting more efficient as it scales, or is growth coming at the cost of margin?
- Revenue concentration: Is growth broad-based across customers and geographies, or dependent on one contract or one region?
- Competitive moat: Does the company have pricing power, switching costs, or network effects that protect the growth rate from competition?
- Balance sheet: Can the company fund its growth without diluting shareholders or taking on dangerous leverage?
Opera Limited (OPRA) scores well on several of these dimensions. Revenue grew
23.2% year-over-year, earnings grew
35.0%, and the forward P/E sits at
10.1. A 4.5% dividend yield on top of that growth rate is unusual and signals genuine cash generation rather than accounting-driven earnings. The ACCE score of
77/100 reflects that combination of growth and financial health.
Compare that to Bed Bath & Beyond (BBBY), which carries a forward P/E of -10.4 and an ACCE score of 11/100. Revenue growth is absent, the balance sheet is distressed, and the analyst target of $9.40 against a current price of $4.57 reflects hope rather than fundamental analysis. High-multiple growth stocks get all the attention, but the real risk in a growth portfolio often comes from holding deteriorating businesses too long.
Step 4: Check the Score Against the Story
Every growth stock comes with a story. The data either confirms the story or contradicts it.
A systematic scoring approach forces that confrontation. When a company's narrative is compelling but the underlying metrics on revenue quality, earnings trajectory, valuation, and business durability all point in a different direction, the data wins. Stories are written by management teams and sell-side analysts with incentives to be optimistic. Numbers are harder to spin.
The ACCE scoring methodology weights these dimensions together, producing a composite view that cuts through narrative. A stock scoring 58/100 like Beam Therapeutics is not a bad company; it is a company where the growth story is real but the financial profile is incomplete. A stock scoring 77/100 like Opera has demonstrated that growth is translating into financial strength across multiple dimensions simultaneously.
Step 5: Build a Checklist, Not a Gut Feel
The practical output of this framework is a checklist applied consistently before any growth stock enters a portfolio:
- Revenue growth rate: Is it accelerating or decelerating over the last four quarters?
- Earnings growth rate: Is it outpacing revenue growth, signaling operating leverage?
- Forward P/E vs. growth rate: Is the market pricing in a realistic or heroic scenario?
- Business quality score: Do the moat, margin, and balance sheet support the growth rate?
- Analyst target gap: Is there a meaningful gap between current price and consensus target that the data supports?
Axon checks most of these boxes. The
$262.57 gap between current price and analyst target ($399.47 vs. $662.04) is substantial, and the earnings growth rate of 89.8% provides a fundamental basis for that gap. The ACCE score of
48/100 is a reminder that valuation risk is real at current levels, which is exactly the kind of tension a checklist surfaces before a position is sized.
Growth stock investing rewards discipline more than conviction. The investors who consistently find compounders before the crowd are not smarter; they are more systematic. The framework above does not guarantee winners, but it eliminates the category of losses that come from buying a story without checking the numbers behind it.
As AI-driven tools make financial data more accessible and analyst coverage more commoditized, the edge in growth stock selection will increasingly belong to investors who apply structured frameworks rather than chasing whatever narrative is loudest in the market.